On October 20, the company reported that its Claude research model helped design toxin-binding proteins; 17 of 211 designs met the study’s binding criteria.
On October 20, Anthropic said an internal Claude research model designed minibinders—small proteins intended to attach to targets—against five scorpion neurotoxins. Over 64 hours, it generated 318,484 designs; Adaptyv Bio and Twist Bioscience tested 211, of which 17 met Anthropic’s binding criteria. The hits targeted four toxins from scorpions found in Mexico, North Africa and the Middle East; none qualified against the Brazilian toxin Ts1. The strongest two, aimed at Mexico’s Cn2 toxin, showed single-digit nanomolar binding affinity. This is a notable step for AI-assisted drug discovery: a model helped move from computational designs to laboratory-tested candidates, potentially giving researchers new starting points for antivenom work. But binding is not neutralization. Anthropic has not shown that the proteins block toxins in cells or protect animals, and says it has not produced an antivenom.